To include your compound in the COVID-19 Resource Center, submit it here.

Afrezza: Phase III start

MannKind said FDA confirmed the protocols of 2 Phase III trials of Afrezza requested by FDA in a January complete response letter. The open-label, international Phase III Study

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE